Amphastar Pharmaceuticals (AMPH) Earns Buy Rating from Wells Fargo

Wells Fargo reaffirmed their buy rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a report published on Wednesday.

Other research analysts have also recently issued research reports about the company. Needham & Company LLC restated a buy rating and issued a $24.00 price target (up previously from $23.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. Piper Jaffray Companies reiterated a buy rating and issued a $26.00 target price on shares of Amphastar Pharmaceuticals in a research report on Tuesday, January 30th. BidaskClub upgraded Amphastar Pharmaceuticals from a sell rating to a hold rating in a research report on Saturday, February 10th. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a sell rating to a hold rating in a research report on Tuesday, January 2nd. Finally, BMO Capital Markets reiterated a market perform rating and issued a $19.00 target price (up previously from $17.00) on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Hold and an average price target of $21.33.

AMPH stock opened at $18.61 on Wednesday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.79 and a quick ratio of 1.85. Amphastar Pharmaceuticals has a 12-month low of $13.15 and a 12-month high of $20.45. The company has a market capitalization of $886.22, a price-to-earnings ratio of 61.68, a P/E/G ratio of 1.56 and a beta of 1.46.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Monday, March 12th. The company reported $0.10 EPS for the quarter, topping the Zacks’ consensus estimate of $0.07 by $0.03. Amphastar Pharmaceuticals had a return on equity of 4.56% and a net margin of 1.88%. The company had revenue of $60.40 million for the quarter, compared to analysts’ expectations of $60.62 million. During the same quarter last year, the business earned $0.01 earnings per share. Amphastar Pharmaceuticals’s revenue was down 4.9% on a year-over-year basis. analysts expect that Amphastar Pharmaceuticals will post 0.54 EPS for the current fiscal year.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 20,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 20th. The stock was sold at an average price of $19.43, for a total value of $388,600.00. Following the transaction, the insider now owns 251,372 shares in the company, valued at $4,884,157.96. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO William J. Peters sold 19,801 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 13th. The shares were sold at an average price of $20.10, for a total value of $398,000.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 84,387 shares of company stock worth $1,659,763. Company insiders own 11.10% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in AMPH. MetLife Investment Advisors LLC bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $350,000. Millennium Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 1,746.9% during the fourth quarter. Millennium Management LLC now owns 293,672 shares of the company’s stock worth $5,650,000 after purchasing an additional 277,771 shares during the last quarter. Paloma Partners Management Co bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $197,000. Stone Ridge Asset Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $214,000. Finally, Driehaus Capital Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the fourth quarter worth about $229,000. Hedge funds and other institutional investors own 44.82% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.tickerreport.com/banking-finance/3296722/amphastar-pharmaceuticals-amph-earns-buy-rating-from-wells-fargo.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Stock Analysts’ Downgrades for April, 27th
Stock Analysts’ Downgrades for April, 27th
Ryder  PT Lowered to $76.00
Ryder PT Lowered to $76.00
The Hackett Group  Stock Rating Lowered by Zacks Investment Research
The Hackett Group Stock Rating Lowered by Zacks Investment Research
IMI  Stock Rating Lowered by Zacks Investment Research
IMI Stock Rating Lowered by Zacks Investment Research
Zacks Investment Research Upgrades Healthcare Trust Of America  to Hold
Zacks Investment Research Upgrades Healthcare Trust Of America to Hold
Croda International  Rating Reiterated by Liberum Capital
Croda International Rating Reiterated by Liberum Capital


© 2006-2018 Ticker Report. Google+.